TR199903142T2 - Pankreas dokusu adac��� transplantasyonu i�in CD154 blokaj tedavisi. - Google Patents

Pankreas dokusu adac��� transplantasyonu i�in CD154 blokaj tedavisi.

Info

Publication number
TR199903142T2
TR199903142T2 TR1999/03142T TR9903142T TR199903142T2 TR 199903142 T2 TR199903142 T2 TR 199903142T2 TR 1999/03142 T TR1999/03142 T TR 1999/03142T TR 9903142 T TR9903142 T TR 9903142T TR 199903142 T2 TR199903142 T2 TR 199903142T2
Authority
TR
Turkey
Prior art keywords
transplant
pancreatic tissue
islet transplantation
blockade therapy
methods
Prior art date
Application number
TR1999/03142T
Other languages
English (en)
Turkish (tr)
Inventor
S. Kenyon Norma
Ricordi Camillo
W. Thomas David
Burkly Linda
Original Assignee
Biogen, Inc.
University Of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc., University Of Miami filed Critical Biogen, Inc.
Publication of TR199903142T2 publication Critical patent/TR199903142T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Steroid Compounds (AREA)
  • External Artificial Organs (AREA)
TR1999/03142T 1997-06-20 1998-06-19 Pankreas dokusu adac��� transplantasyonu i�in CD154 blokaj tedavisi. TR199903142T2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5026797P 1997-06-20 1997-06-20
US7726598P 1998-03-09 1998-03-09

Publications (1)

Publication Number Publication Date
TR199903142T2 true TR199903142T2 (xx) 2000-09-21

Family

ID=26728084

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/03142T TR199903142T2 (xx) 1997-06-20 1998-06-19 Pankreas dokusu adac��� transplantasyonu i�in CD154 blokaj tedavisi.

Country Status (21)

Country Link
US (2) US20030072754A1 (OSRAM)
EP (1) EP1051191B1 (OSRAM)
JP (1) JP2002506446A (OSRAM)
KR (1) KR100634847B1 (OSRAM)
CN (2) CN1195546C (OSRAM)
AT (1) ATE339966T1 (OSRAM)
AU (1) AU730763B2 (OSRAM)
BG (1) BG64976B1 (OSRAM)
BR (1) BR9810620A (OSRAM)
CA (1) CA2294154A1 (OSRAM)
DE (1) DE69835965T2 (OSRAM)
EA (1) EA002550B1 (OSRAM)
EE (1) EE9900588A (OSRAM)
HU (1) HUP0003160A3 (OSRAM)
IL (1) IL133303A0 (OSRAM)
IS (1) IS5273A (OSRAM)
NO (1) NO996275L (OSRAM)
NZ (1) NZ502052A (OSRAM)
SK (1) SK180299A3 (OSRAM)
TR (1) TR199903142T2 (OSRAM)
WO (1) WO1998058669A2 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045958A1 (en) * 1998-03-09 1999-09-16 Biogen, Inc. Cd154 blockade therapy for modulation of immune responses to implanted devices
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU2001275186A1 (en) * 2000-06-02 2001-12-17 Nicole Kirchhof Immunotherapeutic method to prevent islet cell rejection
EP1294391B1 (en) * 2000-06-09 2012-08-15 Bristol-Myers Squibb Company Combination of agents for inhibiting transplant rejection
DE602004029252D1 (de) * 2003-06-13 2010-11-04 Biogen Idec Inc Aglycosyl-anti-cd154 (cd40-ligand) antikörper und deren verwendungen
CZ200755A3 (cs) 2004-07-26 2007-04-11 Biogen Idec Ma Inc. Peptidy protilátek anti-CD154
WO2006054305A2 (en) * 2004-11-22 2006-05-26 Ramot At Tel Aviv University Ltd. Populations of expanded and re-differentiated adult islet beta cells capable of producing insulin and methods of generating same
US20070087029A1 (en) * 2005-10-14 2007-04-19 Pakala Syamasundar V Localized delivery to the lymphatic system
US8372399B2 (en) 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US8636995B2 (en) 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
EP2396348B1 (en) * 2009-02-10 2015-04-08 The Trustees of Columbia University in the City of New York Compositions comprising hla-e for use in methods for inducing transplantation tolerance
WO2011146395A2 (en) 2010-05-17 2011-11-24 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10147463B2 (en) 2014-12-10 2018-12-04 Nxp Usa, Inc. Video processing unit and method of buffering a source video stream
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
KR101810778B1 (ko) * 2015-06-23 2017-12-20 서울대학교산학협력단 Cd154 결합 폴리펩타이드 및 그 용도
US10986309B2 (en) 2015-06-30 2021-04-20 Nxp Usa, Inc. Video buffering and frame rate doubling device and method
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227298A (en) * 1990-08-17 1993-07-13 The Trustees Of Columbia University In The City Of New York Method for microencapuslation of cells or tissue
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
AU710998B2 (en) * 1996-03-20 1999-10-07 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4 /CD28/B7 pathways and compositions for use therewith

Also Published As

Publication number Publication date
BR9810620A (pt) 2000-10-03
US20030072754A1 (en) 2003-04-17
AU7983098A (en) 1999-01-04
NZ502052A (en) 2001-01-26
EE9900588A (et) 2000-08-15
DE69835965T2 (de) 2007-06-14
JP2002506446A (ja) 2002-02-26
CA2294154A1 (en) 1998-12-30
HUP0003160A3 (en) 2002-09-30
KR100634847B1 (ko) 2006-10-17
SK180299A3 (en) 2000-06-12
HUP0003160A2 (hu) 2001-01-29
WO1998058669A3 (en) 1999-04-29
EP1051191B1 (en) 2006-09-20
HK1033548A1 (en) 2001-09-07
DE69835965D1 (de) 2006-11-02
EA002550B1 (ru) 2002-06-27
US20070292440A1 (en) 2007-12-20
BG104091A (en) 2000-10-31
CN1651919A (zh) 2005-08-10
CN1261286A (zh) 2000-07-26
WO1998058669A2 (en) 1998-12-30
CN1195546C (zh) 2005-04-06
AU730763B2 (en) 2001-03-15
EP1051191A2 (en) 2000-11-15
IL133303A0 (en) 2001-04-30
EA200000058A1 (ru) 2000-08-28
KR20010013965A (ko) 2001-02-26
BG64976B1 (bg) 2006-11-30
NO996275D0 (no) 1999-12-17
NO996275L (no) 2000-02-21
ATE339966T1 (de) 2006-10-15
IS5273A (is) 1999-11-26

Similar Documents

Publication Publication Date Title
Najjar et al. Fibrin gels engineered with pro‐angiogenic growth factors promote engraftment of pancreatic islets in extrahepatic sites in mice
AU7432796A (en) Retrievable bioartificial implants
CA2387542A1 (en) Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation
EA200000058A1 (ru) Лечение посредством блокады cd154 при трансплантации ткани панкреатических островков
DE69525151D1 (de) Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
DE69634982D1 (de) Verfahren zur steigerung von hematopoietischen zellen
EP1233058A4 (en) PROCESS FOR THE REPRODUCTION OF NATURAL KILLER CELLS
BR9612821A (pt) Métodos para a prevenção de rejeição de enxerto em transplante e para a produção de uma célula de hospedeiro para terapia genética universal
DE69624937D1 (de) Verfahren zur verminderung der strahlentherapie oder der radiomimetischen chemotherapie bei der transplantation von hematopoietischen, pluripotenten zellen
FI961440A0 (fi) Insuliinia erittäviä solulinjoja, valmistusmenetelmiä ja käyttö
GB2397825B (en) Method of producing human beta cell lines
ATE264112T1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
WO2005059095A3 (en) Expansion and differentiation of islet progenitor cells
DE50004024D1 (de) Verwendung von treosulfan zur konditionierung von patienten vor knochenmarktransplantation oder blutstammzelltransplantation
Hodgson Liver cells: biology to therapeutics
ATE279945T1 (de) Verwendung von coxiella bakterien zur behandlung von autoimmunkrankheiten
Soldan Adaptation of the subimaginal life span of Cloeon(Ephemeroptera, Baetidae) in the arid areas of North Africa and the Canary Islands.
ATE69551T1 (de) Zusammensetzung zur behandlung von boesartigen tumoren insbesondere bei tieren.
Gupta et al. Comparison of Immunomodulation by Cyclosporin A and Azathioprine on Pancreatic Xenograft Survival
Sandberg Immunoprotective strategies in allo-and xenogeneic transplantation of insulin-producing cells.
SHAMBAUGH Organ Transplantation
Wagner et al. Pancreatic Stem Cells. Perspectives for Transplantation Therapy
WO2004078956A3 (en) Process for detaching confluent cells from two dimensional microsupports and its application for preparing transplants
GB2358861A (en) Substances from porcine tissue
MX9604845A (es) Crecimiento in vitro de islotes de langerhans funcionales y uso in vivo de los mismos.